Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre E Escargueil

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Molecular Cancer Therapeutics|May 31, 2011
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cellsDaniele G Soares, Miriana S Machado, Céline J Rocca, et al.
International Journal of Molecular Sciences|July 27, 2022
The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1Chloé Borde, Clémentine Dillard, Aurore L'Honoré, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodiesVirginie Poindessous, Djamila Ouaret, Karima El Ouadrani, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Molecular Cancer Therapeutics|May 31, 2011
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cellsDaniele G Soares, Miriana S Machado, Céline J Rocca, et al.
International Journal of Molecular Sciences|July 27, 2022
The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1Chloé Borde, Clémentine Dillard, Aurore L'Honoré, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodiesVirginie Poindessous, Djamila Ouaret, Karima El Ouadrani, et al.
Pageof 4